Beryl Drugs Limited has disclosed another share acquisition by its promoter and director Mr. Sudhir Sethi, who acquired 3,040 shares under SEBI's Insider Trading Regulations. This latest transaction on 13-03-2026 represents 0.06% of the company's total share capital, demonstrating continued promoter confidence in the pharmaceutical company.

Transaction Details and Regulatory Compliance

The acquisition was disclosed under Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015, with the company filing the disclosure on 14-03-2026. Mr. Sudhir Sethi (DIN: 00090172) purchased the shares through market transactions on BSE, with the disclosure submitted to The Bombay Stock Exchange Limited.

Updated Shareholding Pattern

With this latest acquisition, Mr. Sudhir Sethi's stake has increased from 9.27% to 9.33% of the total equity share capital. The disclosure shows his holding increased from 4,70,143 shares to 4,73,183 shares, representing continued commitment to the company's growth prospects.

Corporate Structure and Management

Beryl Drugs Limited maintains its registered office at Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.), with CIN L02423MP1993PLC007840. The disclosure was properly submitted by Managing Director Sanjay Sethi (DIN: 00090277) on behalf of the company, ensuring compliance with regulatory requirements for insider trading disclosures. The company's ISIN is INE415H00017, and it maintains regular communication through beryldrugs25@yahoo.com .

Beryl Drugs Limited has reported challenging financial results for the third quarter of fiscal year 2026, posting a net loss of ₹16.77 lacs compared to a profit of ₹5.22 lacs in the same quarter of the previous year. The pharmaceutical company's performance was significantly impacted by operational disruptions and declining revenue during the quarter ended December 31, 2025.

Financial Performance Overview

The company's financial metrics showed a marked deterioration across key parameters during Q3 FY26:

Operational Challenges and Recovery

A significant factor affecting the company's performance was the suspension of part of its manufacturing facility. The facility was suspended with effect from February 11, 2025, following directions issued by the State Food and Drugs Administration (FDA) for upgradation purposes.

The company responded proactively by submitting a comprehensive point-wise rectification and compliance report along with supporting documents and photographs. Following regulatory review, the State Food and Drugs Administration permitted continuation of operations of the concerned section with effect from November 28, 2025, lifting the suspension.

Cost Structure Analysis

Despite the revenue decline, the company managed to reduce several cost components:

Year-to-Date Performance

The nine-month performance for the period ended December 31, 2025, also reflected challenges, with the company reporting a net loss of ₹13.77 lacs compared to a profit of ₹42.70 lacs in the corresponding period of the previous year. Year-to-date revenue declined to ₹1,369.11 lacs from ₹1,717.26 lacs in the previous year.

Earnings Per Share Impact

The financial performance translated into negative earnings per share, with both basic and diluted EPS at ₹-0.33 for Q3 FY26, compared to positive ₹0.10 in Q3 FY25. The company maintained its paid-up equity share capital at ₹507.17 lacs with a face value of ₹10.00 per share.

Regulatory Compliance and Outlook

The company's financial results were prepared in accordance with Indian Accounting Standards and were subject to limited review by statutory auditors. The Board of Directors approved these unaudited financial results in their meeting held on February 9, 2026, ensuring compliance with SEBI listing regulations. With the manufacturing facility suspension now lifted and operations resumed, the company appears positioned to address the operational challenges that impacted its Q3 FY26 performance.